Exagen Inc. (XGN) stock
XGNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3010% above fair value
$3.76−0.01 (-0.27%)
Close on Nov 17, 2026Market cap $91.09MP/E –Yield –
Exagen r&d expenses
Research and development expenses are spending on new products and technology.
Exagen's R&D Expenses for the twelve months ending Jun 30, 2026 was $6.47M, up 9.5% year over year. For fiscal 2025 it was $6.25M, up 16.4% from the year before. The highest annual figure on record is $9.88M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.25M | +16.4% |
| FY2024 | Dec 31, 2024 | $5.38M | +10.5% |
| FY2023 | Dec 31, 2023 | $4.87M | -50.7% |
| FY2022 | Dec 31, 2022 | $9.88M | +36.5% |
| FY2021 | Dec 31, 2021 | $7.24M | +102.8% |
| FY2020 | Dec 31, 2020 | $3.57M | +64.0% |
| FY2019 | Dec 31, 2019 | $2.18M | +2.4% |
| FY2018 | Dec 31, 2018 | $2.13M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.43M | -3.8% |
| Q1 FY2026 | Mar 31, 2026 | $1.55M | +21.0% |
| Q4 FY2025 | Dec 31, 2025 | $1.76M | +6.1% |
| Q3 FY2025 | Sep 30, 2025 | $1.73M | +16.8% |
| Q2 FY2025 | Jun 30, 2025 | $1.48M | +25.8% |
| Q1 FY2025 | Mar 31, 2025 | $1.28M | +21.2% |
| Q4 FY2024 | Dec 31, 2024 | $1.66M | +53.9% |
| Q3 FY2024 | Sep 30, 2024 | $1.48M | +5.8% |
| Q2 FY2024 | Jun 30, 2024 | $1.18M | -6.7% |
| Q1 FY2024 | Mar 31, 2024 | $1.06M | -6.0% |
| Q4 FY2023 | Dec 31, 2023 | $1.08M | -60.2% |
| Q3 FY2023 | Sep 30, 2023 | $1.40M | -41.2% |
| Q2 FY2023 | Jun 30, 2023 | $1.26M | -53.0% |
| Q1 FY2023 | Mar 31, 2023 | $1.13M | -46.5% |
| Q4 FY2022 | Dec 31, 2022 | $2.70M | +22.7% |
| Q3 FY2022 | Sep 30, 2022 | $2.38M | +36.9% |
| Q2 FY2022 | Jun 30, 2022 | $2.69M | +42.1% |
| Q1 FY2022 | Mar 31, 2022 | $2.10M | +50.0% |
| Q4 FY2021 | Dec 31, 2021 | $2.20M | +89.0% |
| Q3 FY2021 | Sep 30, 2021 | $1.74M | +70.9% |
| Q2 FY2021 | Jun 30, 2021 | $1.89M | +151.9% |
| Q1 FY2021 | Mar 31, 2021 | $1.40M | +121.3% |
| Q4 FY2020 | Dec 31, 2020 | $1.17M | +105.8% |
| Q3 FY2020 | Sep 30, 2020 | $1.02M | +100.8% |
| Q2 FY2020 | Jun 30, 2020 | $751.00K | +27.3% |
| Q1 FY2020 | Mar 31, 2020 | $634.00K | +23.6% |
| Q4 FY2019 | Dec 31, 2019 | $566.00K | +6.2% |
| Q3 FY2019 | Sep 30, 2019 | $507.00K | -3.4% |
| Q2 FY2019 | Jun 30, 2019 | $590.00K | – |
| Q1 FY2019 | Mar 31, 2019 | $513.00K | – |
| Q4 FY2018 | Dec 31, 2018 | $533.00K | – |
| Q3 FY2018 | Sep 30, 2018 | $525.00K | – |
See a number that looks wrong?